Subscribe

Cipla Limited (CIPLA.NS)

INR1,426.70 -12.70 (-0.88%)
IN NSE Healthcare Drug Manufacturers - General
Address Cipla House 400013
Mumbai, MA, IN
CEO Achin Gupta
Website cipla.com
IPO 1996-01-01
ISIN INE059A01026

Explore sections of this company profile

Also trades on Bombay Stock Exchange · CIPLA.BO (INR) National Stock Exchange of India · CIPLA.NS (INR)
Description

Cipla Limited, along with its associated entities, operates as a global pharmaceutical enterprise, specializing in the creation and distribution of a wide array of medicinal products. Its extensive portfolio includes both active pharmaceutical ingredients (APIs) and a diverse range of finished formulations, addressing numerous therapeutic areas such as cardiovascular diseases, metabolic disorders, HIV, respiratory conditions, urology, oncology, pediatric health, infectious diseases, critical care, hepatitis, women's health, ophthalmology, and neuropsychiatry. The company maintains a strong focus on respiratory treatments, offering various inhalers, nasal sprays, injectables, and biosimilars. Cipla has also forged significant partnerships, including a licensing arrangement with Merck & Co., Inc. for the manufacturing and commercialization of the investigational oral antiviral drug Molnupiravir, and a separate license agreement with Eli Lilly and Company for baricitinib, indicated for COVID-19. Furthermore, it collaborates with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for Molnupiravir's clinical trials. Established in 1935, Cipla's corporate headquarters are located in Mumbai, India.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
INR1,426.70 -12.70 (-0.88%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
0.11
Float Shares
563.41M
Free Float %
69.7%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+8.22% +6.03% +17.09% +7.90% -6.23% -4.94% -3.89% +55.69% +58.92% +175.34% +6,021.43%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
1,426.70
DCF (Unlevered) 3,644.48 +155.4%
DCF (Levered) 3,520.44 +146.8%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 46% Bullish
Rating 2026-05 Change
Strong Buy 8 0
Buy 9 0
Hold 12 0
Sell 4 -1
Strong Sell 4 -1
Quality scores
Altman Z-Score
10.28
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Drug Manufacturers - General: +6.6%
    +3.3% Q1'26: -2.7% (vs Q1'25)
  • ✗
    EPS growth Drug Manufacturers - General: +18.2%
    -26.4% Q1'26: -54.6% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Drug Manufacturers - General: +36.0%
    +10.9% Q1'26: +10.4% (vs Q1'25)
  • ✗
    EBIT margin Drug Manufacturers - General: +19.4%
    +16.7% Q1'26: +9.4% (vs Q1'25)
  • ✗
    ROIC Drug Manufacturers - General: +10.2%
    +13.4% ★ Q1'26: +7.3% (vs Q1'25)
  • ✓
    Share dilution Drug Manufacturers - General: +0.0%
    +0.0% Q1'26: +0.1% (vs Q1'25)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×
    0.10× ★ Q1'26: 0.15× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.66) × ERP
WACC = 99% × Ke + 1% × Kd (8.9%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 1,213.65 Current price: 1,426.70
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Mar 2011
actual 		Mar 2012
actual 		Mar 2013
actual 		Mar 2014
actual 		Mar 2015
actual 		Mar 2016
actual 		Mar 2017
actual 		Mar 2018
actual 		Mar 2019
actual 		Mar 2020
actual 		Mar 2021
actual 		Mar 2022
actual 		Mar 2023
actual 		Mar 2024
actual 		Mar 2025
actual 		Mar 2026
34 Rev. Ana.
27 EPS Ana. 		Mar 2027
30 Rev. Ana.
29 EPS Ana. 		Mar 2028
32 Rev. Ana.
29 EPS Ana. 		Mar 2029
9 Rev. Ana.
7 EPS Ana. 		Mar 2030
4 Rev. Ana.
2 EPS Ana.
Revenue
1.44B
est: 62.31B (-97.7%)
70.21B
est: 70.25B (-0.1%)
82.79B
est: 83.81B (-1.2%)
113.45B
est: 101.08B (+12.2%)
113.45B
est: 111.60B (+1.7%)
135.48B
est: 136.92B (-1.1%)
143.34B
est: 150.73B (-4.9%)
151.05B
est: 156.58B (-3.5%)
163.23B
est: 161.12B (+1.3%)
170.81B
est: 171.11B (-0.2%)
191.21B
est: 195.47B (-2.2%)
217.08B
est: 216.84B (+0.1%)
225.59B
est: 228.20B (-1.1%)
255.37B
est: 258.92B (-1.4%)
272.67B
est: 274.82B (-0.8%)
283.32B
278.17B – 288.48B
+3.1% YoY
309.59B
300.18B – 320.54B
+9.3% YoY
345.31B
328.33B – 362.17B
+11.5% YoY
377.30B
376.97B – 377.63B
+9.3% YoY
441.99B
424.20B – 460.75B
+17.1% YoY
EBITDA
14.53B
est: 16.18B (-10.2%)
17.84B
est: 16.07B (+11.0%)
22.20B
est: 21.11B (+5.1%)
21.70B
est: 29.93B (-27.5%)
21.70B
est: 25.79B (-15.9%)
24.71B
est: 25.32B (-2.4%)
25.13B
est: 26.26B (-4.3%)
28.04B
est: 26.09B (+7.5%)
30.98B
est: 31.76B (-2.5%)
30.79B
est: 37.92B (-18.8%)
41.24B
est: 37.59B (+9.7%)
44.39B
est: 40.84B (+8.7%)
49.19B
est: 43.77B (+12.4%)
61.91B
est: 81.32B (-23.9%)
70.22B
est: 86.90B (-19.2%)
88.99B
87.37B – 90.61B
+2.4% YoY
97.24B
94.28B – 100.68B
+9.3% YoY
108.46B
103.12B – 113.75B
+11.5% YoY
118.50B
118.40B – 118.61B
+9.3% YoY
138.82B
133.23B – 144.71B
+17.1% YoY
EBIT
11.80B
est: 10.66B (+10.6%)
14.72B
est: 9.80B (+50.2%)
18.89B
est: 16.51B (+14.4%)
16.66B
est: 24.72B (-32.6%)
16.66B
est: 19.86B (-16.1%)
17.41B
est: 20.55B (-15.3%)
16.71B
est: 18.90B (-11.6%)
18.91B
est: 12.55B (+50.7%)
20.41B
est: 14.80B (+37.9%)
21.20B
est: 18.70B (+13.4%)
32.49B
est: 22.24B (+46.1%)
35.63B
est: 24.16B (+47.5%)
40.08B
est: 25.89B (+54.8%)
53.49B
est: 76.62B (-30.2%)
61.29B
est: 81.87B (-25.1%)
83.84B
82.31B – 85.37B
+2.4% YoY
91.61B
88.83B – 94.85B
+9.3% YoY
102.18B
97.16B – 107.17B
+11.5% YoY
111.65B
111.55B – 111.75B
+9.3% YoY
130.79B
125.53B – 136.34B
+17.1% YoY
Net Income
9.90B
est: 12.00B (-17.5%)
11.44B
est: 10.92B (+4.8%)
15.45B
est: 13.65B (+13.2%)
13.88B
est: 18.63B (-25.5%)
11.81B
est: 15.51B (-23.9%)
13.60B
est: 14.63B (-7.1%)
10.06B
est: 14.88B (-32.4%)
14.11B
est: 10.43B (+35.3%)
15.28B
est: 14.58B (+4.8%)
15.47B
est: 16.07B (-3.8%)
24.05B
est: 16.85B (+42.7%)
25.17B
est: 18.31B (+37.5%)
28.02B
est: 19.62B (+42.8%)
41.22B
est: 43.03B (-4.2%)
52.73B
est: 53.93B (-2.2%)
41.38B
34.42B – 47.76B
-23.3% YoY
43.38B
34.24B – 51.79B
+4.8% YoY
51.91B
45.69B – 59.74B
+19.6% YoY
57.04B
53.17B – 64.70B
+9.9% YoY
87.04B
82.49B – 91.84B
+52.6% YoY
SGA
5.36B
est: 4.79B (+11.8%)
6.80B
est: 17.36B (-60.8%)
21.03B
est: 24.52B (-14.2%)
23.55B
est: 30.98B (-24.0%)
23.55B
est: 33.76B (-30.2%)
29.26B
est: 45.97B (-36.4%)
33.01B
est: 49.10B (-32.8%)
34.15B
est: 51.10B (-33.2%)
37.42B
est: 53.65B (-30.3%)
38.69B
est: 60.08B (-35.6%)
41.28B
est: 67.59B (-38.9%)
46.67B
est: 73.44B (-36.5%)
50.15B
est: 78.70B (-36.3%)
54.90B
est: 56.56B (-2.9%)
61.07B
est: 60.44B (+1.0%)
61.89B
60.76B – 63.01B
+2.4% YoY
67.62B
65.57B – 70.02B
+9.3% YoY
75.43B
71.72B – 79.11B
+11.5% YoY
82.41B
82.34B – 82.49B
+9.3% YoY
96.54B
92.66B – 100.64B
+17.1% YoY
EPS
12.32
est: 13.15 (-6.3%)
14.25
est: 14.45 (-1.4%)
19.24
est: 20.02 (-3.9%)
17.29
est: 18.32 (-5.6%)
14.71
est: 16.23 (-9.3%)
16.93
est: 22.09 (-23.4%)
12.52
est: 18.25 (-31.4%)
17.53
est: 20.33 (-13.8%)
18.97
est: 18.32 (+3.6%)
19.19
est: 20.33 (-5.6%)
29.82
est: 32.13 (-7.2%)
31.20
est: 35.24 (-11.5%)
34.72
est: 37.37 (-7.1%)
51.05
est: 53.29 (-4.2%)
65.29
est: 60.46 (+8.0%)
52.03
42.60 – 59.10
-13.9% YoY
52.22
42.37 – 64.09
+0.4% YoY
64.05
56.54 – 73.92
+22.7% YoY
72.32
65.80 – 80.05
+12.9% YoY
107.70
102.06 – 113.64
+48.9% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-14 A- 4/5 5/5 4/5 5/5 3/5 2/5 2/5
2026-05-13 C 2/5 5/5 1/5 1/5 1/5 2/5 1/5
2026-05-12 C 2/5 5/5 1/5 1/5 1/5 2/5 1/5
2026-05-11 C 2/5 5/5 1/5 1/5 1/5 2/5 1/5
2026-05-08 C 2/5 5/5 1/5 1/5 1/5 2/5 1/5
2026-05-07 C 2/5 5/5 1/5 1/5 1/5 2/5 1/5
2026-05-06 C 2/5 5/5 1/5 1/5 1/5 2/5 1/5
2026-05-05 C 2/5 5/5 1/5 1/5 1/5 2/5 1/5
2026-05-04 C 2/5 5/5 1/5 1/5 1/5 2/5 1/5
2026-04-30 C 2/5 5/5 1/5 1/5 1/5 2/5 1/5
2026-04-29 C 2/5 5/5 1/5 1/5 1/5 2/5 1/5
2026-04-28 C 2/5 5/5 1/5 1/5 1/5 2/5 1/5
2026-04-27 C 2/5 5/5 1/5 1/5 1/5 2/5 1/5
2026-04-24 C 2/5 5/5 1/5 1/5 1/5 2/5 1/5
2026-04-23 C 2/5 5/5 1/5 1/5 1/5 2/5 1/5
2026-04-22 C 2/5 5/5 1/5 1/5 1/5 2/5 1/5
2026-04-21 C 2/5 5/5 1/5 1/5 1/5 2/5 1/5
2026-04-20 C 2/5 5/5 1/5 1/5 1/5 2/5 1/5
2026-04-17 C 2/5 5/5 1/5 1/5 1/5 2/5 1/5
2026-04-16 C 2/5 5/5 1/5 1/5 1/5 2/5 1/5
2026-04-15 C 2/5 5/5 1/5 1/5 1/5 2/5 1/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
5.18B
OE per share TTM
6.41
Owner's Yield
0.45%
Maintenance CapEx ratio
6.82%
Maint CapEx / Avg PPE
26.6%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
1.70M
Shares Outstanding
807.78M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Umang Vohra MD, Global Chief Executive Officer & Executive Director 239M male
Rajendra Kumar Chopra Compliance Officer & Company Secretary 15M male
Arun Kakatkar Global Chief People Officer — male
Ashish Adukia Global Chief Financial Officer — male
Diksha Maheshwari Head of Investor Relations — female
Dinesh Ramniranjan Jain Senior Vice President & Head of Corporate Finance — male
A. S. Kumar Global General Counsel — —
Meera Vanjari Global General Counsel — female
Pradeep Bhadauria President & Global Chief Scientific Officer — male
Sneha Hiranandani Chief Information Officer — female
Heena Kanal Senior Vice-President of Corporate Communications — female
Achin Gupta MD, Global CEO & Additional Director — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - General